Leerink Partners Maintains Outperform on Eli Lilly, Raises Price Target to $1316

Benzinga · 2d ago
Leerink Partners analyst David Risinger maintains Eli Lilly (NYSE:LLY) with a Outperform and raises the price target from $1309 to $1316.